Trial Profile
Protocol ALL-11: Treatment study protocol of the Dutch Childhood Oncology Group for children and adolescents (1-19 year) with newly diagnosed acute lymphoblastic leukemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Jan 2024
Price :
$35
*
At a glance
- Drugs Pegaspargase (Primary) ; Crisantaspase; Immune globulin
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms ALL11
- 12 Dec 2023 Results reporting safety and efficacy data at a median follow-up of over 57 months presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 16 Jul 2023 Status changed from recruiting to completed.
- 15 Feb 2021 Planned number of patients changed from 630 to 819.